Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 15/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884179 | 0.85 | S1PR5 (0.39) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL883931 | 0.84 | MAPT (0.47) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL3275809 | 0.78 | BRD4 (0.38) | S1PR1MEN1KMT2A | |
| SCHEMBL1830735 | 0.78 | S1PR5 (0.39) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL1858232 | 0.76 | MAPK1 (0.31) | — | |
| SCHEMBL4678480 | 0.75 | POLB (0.53) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL2353875 | 0.72 | S1PR5 (0.41) | S1PR5S1PR1S1PR3S1PR4 | |
| SCHEMBL13905850 | 0.72 | S1PR5 (0.42) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL30479891 | 0.72 | POLB (0.42) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL29226681 | 0.72 | S1PR5 (0.38) | S1PR5S1PR1POLBS1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103313981-B | 2-methoxyl group-pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-11 | — | — | CN | claimed |
| US-9133179-B2 | 2-methoxy-pyridin-4-yl-derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-09-15 | — | — | US | claimed |
| EP-2665720-B1 | 2-METHOXY-PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2125797-B1 | AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-15 | — | — | EP | claimed |
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | claimed |
| EP-2665720-A1 | 2-METHOXY-PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-11-27 | — | — | EP | claimed |
| US-20130303514-A1 | 2-METHOXY-PYRIDIN-4-YL-DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-14 | — | — | US | claimed |
| EP-2252609-B1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-17 | — | — | EP | claimed |
| US-8410151-B2 | Aminomethyl benzene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-02 | — | — | US | claimed |
| EP-2222667-B1 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-20 | — | — | EP | claimed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | claimed |
| EP-1896446-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-12 | — | — | EP | claimed |
| EP-1863474-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| EP-1863475-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| WO-2007046075-A1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-04-26 | — | — | WO | claimed |
| WO-2006137019-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-28 | — | — | WO | claimed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
| WO-2006100633-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
| WO-2006100635-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303514-A1 | 2-METHOXY-PYRIDIN-4-YL-DERIVATIVES | CD4, IL2, IL4 | S1PR5 200/4885S1PR1 121/4885POLB 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.